The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Review Article

Antibody-Drug Conjugates in the Management of Breast Cancer

Authors: Sangeetha Isaac, MD, Sameer Batoo, MD

Abstract

Breast cancer remains a predominant contributor to global cancer-related morbidity and mortality among women, with its incidence steadily rising and presenting complex therapeutic challenges. Conventional treatment modalities, including chemotherapy, endocrine therapy, and molecularly targeted interventions, have demonstrated substantial clinical efficacy. The emergence of therapeutic resistance, systemic cytotoxicity, and metastatic progression continues to impede optimal treatment outcomes, however. Antibody-drug conjugates (ADCs) represent an advanced class of targeted therapeutics engineered to deliver cytotoxic agents selectively to malignant cells, thereby augmenting antitumor efficacy while mitigating off-target toxicities. This review provides a comprehensive analysis of the molecular mechanisms underpinning ADC activity, evaluates the current clinical landscape, and examines the inherent challenges in ADC-based breast cancer therapy. In addition, it discusses the clinical utility of Food and Drug Administration approved ADCs, ongoing clinical trials, and prospective advancements in ADC development.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Global burden of cancer. Lancet Oncol 2020;21:885–899.
 
2. Breast cancer subtypes. NCBI Bookshelf 2021; NBK583808.
 
3. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies. Signal Transduct Target Ther 2024;9.
 
4. Linker technologies for antibody–drug conjugates. Methods Mol Biol 2013;1045:71–100.
 
5. Antibody–drug conjugates: Recent advances in payloads. Acta Pharm Sin B 2023;13: 4025–4059.
 
6. DESTINY-Breast01 trial. N Engl J Med 2020;382:610–621.
 
7. T-DXd in HER2-low breast cancer. Lancet Oncol 2022;23:456–465.
 
8. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401:1773–1785.
 
9. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9–20.
 
10. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:732–742.
 
11. von Minckwitz G, Huang CS, Mano MS, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive HER2-positive breast cancer. N Engl J Med 2019;380: 617–628. doi:10.1056/NEJMoa1812617
 
12. ASCENT trial. Lancet Oncol 2020;21:1197–1207.
 
13. Rugo HS, Bardia A, DeMichele A, et al. Sacituzumab govitecan in hormone receptor–positive/HER2–negative metastatic breast cancer (TROPiCS-02): a randomized, open-label, phase 3 trial. Lancet Oncol 2022;23:959–971. doi:10.1016/S1470-2045(22) 00228-3.
 
14. TROPION-Breast01 trial. J Clin Oncol 2021;39:3755–3764.
 
15. Abelman RO, Wu B, Spring LM, et al. Mechanisms of resistance to antibody-drug conjugates. Cancer (Basel) 2023;15:1278. doi:10.3390/cancers15041278.
 
16. Mechanisms of resistance to antibody–drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resist 2025;8:59.
 
17. Combining antibody–drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 2022;106:102395